Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015 (2015), Article ID 232048, 7 pages
http://dx.doi.org/10.1155/2015/232048
Research Article

The Relation between eNOS −786 C/T, 4 a/b, MMP-13 rs640198 G/T, Eotaxin 426 C/T, −384 A/G, and 67 G/A Polymorphisms and Long-Term Outcome in Patients with Coronary Artery Disease

1Department of Internal Medicine/Cardioangiology and ICRC, St. Anne’s University Hospital, Faculty of Medicine, Masaryk University, Pekařská 53, 656 91 Brno, Czech Republic
2Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic

Received 17 March 2015; Revised 3 July 2015; Accepted 13 September 2015

Academic Editor: Mariann Harangi

Copyright © 2015 Vladimír Kincl et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Abraham, O. G. Bhalala, P. I. W. de Bakker, S. Ripatti, and M. Inouye, “Towards a molecular systems model of coronary artery disease,” Current Cardiology Reports, vol. 16, article 488, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. B. P. Prins, V. Lagou, F. W. Asselbergs, H. Snieder, and J. Fu, “Genetics of coronary artery disease: genome-wide association studies and beyond,” Atherosclerosis, vol. 225, no. 1, pp. 1–10, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Koch, J. Mehilli, A. Pfeufer, A. Schömig, and A. Kastrati, “Apolipoprotein E gene polymorphisms and thrombosis and restenosis after coronary artery stenting,” Journal of Lipid Research, vol. 45, no. 12, pp. 2221–2226, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Blankenberg, H. J. Rupprecht, C. Bickel et al., “Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease,” Journal of the American College of Cardiology, vol. 41, no. 11, pp. 1983–1989, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Szpakowicz, W. Pepinski, E. Waszkiewicz et al., “The influence of renal function on the association of rs854560 polymorphism of paraoxonase 1 gene with long-term prognosis in patients after myocardial infarction,” Heart and Vessels, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Maiolino, L. Lenzini, L. Pedon et al., “Lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms and cardiovascular events in patients with coronary artery disease,” Journal of Cardiovascular Medicine, vol. 16, no. 1, pp. 29–36, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. K. L. Ellis, C. M. Frampton, A. P. Pilbrow et al., “Genomic risk variants at 1p13.3, 1q41, and 3q22.3 are associated with subsequent cardiovascular outcomes in healthy controls and in established coronary artery disease,” Circulation: Cardiovascular Genetics, vol. 4, no. 6, pp. 636–646, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. D. E. Arking and A. Chakravarti, “Understanding cardiovascular disease through the lens of genome-wide association studies,” Trends in Genetics, vol. 25, no. 9, pp. 387–394, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. The Wellcome Trust Case Control Consortium, “Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls,” Nature, vol. 447, no. 7145, pp. 661–678, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Helgadottir, G. Thorleifsson, A. Manolescu et al., “A common variant on chromosome 9p21 affects the risk of myocardial infarction,” Science, vol. 316, no. 5830, pp. 1491–1493, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. R. McPherson, A. Pertsemlidis, N. Kavaslar et al., “A common allele on chromosome 9 associated with coronary heart disease,” Science, vol. 316, no. 5830, pp. 1488–1491, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. N. J. Samani, J. Erdmann, A. S. Hall et al., “Genomewide association analysis of coronary artery disease,” The New England Journal of Medicine, vol. 357, no. 5, pp. 443–453, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Schunkert, A. Götz, P. Braund et al., “Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease,” Circulation, vol. 117, no. 13, pp. 1675–1684, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Brautbar, C. M. Ballantyne, K. Lawson et al., “Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the atherosclerosis risk in communities study,” Circulation: Cardiovascular Genetics, vol. 2, no. 3, pp. 279–285, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Bäck, D. F. J. Ketelhuth, and S. Agewall, “Matrix metalloproteinases in atherothrombosis,” Progress in Cardiovascular Diseases, vol. 52, no. 5, pp. 410–428, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. K. J. Haley, C. M. Lilly, J.-H. Yang et al., “Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation,” Circulation, vol. 102, no. 18, pp. 2185–2189, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. J.-O. Deguchi, E. Aikawa, P. Libby et al., “Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques,” Circulation, vol. 112, no. 17, pp. 2708–2715, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Yoon, H. Kuivaniemi, Z. Gatalica et al., “MMP13 promoter polymorphism is associated with atherosclerosis in the abdominal aorta of young black males,” Matrix Biology, vol. 21, no. 6, pp. 487–498, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Vašku, J. Meluzín, J. Blahák et al., “Matrix metalloproteinase 13 genotype in rs640198 polymorphism is associated with severe coronary artery disease,” Disease Markers, vol. 33, no. 1, pp. 43–49, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Van Coillie, J. Van Damme, and G. Opdenakker, “The MCP/eotaxin subfamily of CC chemokines,” Cytokine & Growth Factor Reviews, vol. 10, no. 1, pp. 61–86, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Emanuele, C. Falcone, A. D'Angelo et al., “Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease,” Atherosclerosis, vol. 186, no. 1, pp. 140–145, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Raaz-Schrauder, L. Klinghammer, C. Baum et al., “Association of systemic inflammation markers with the presence and extent of coronary artery calcification,” Cytokine, vol. 57, no. 2, pp. 251–257, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Miyamasu, T. Sekiya, K. Ohta et al., “Variations in the human CC chemokine eotaxin gene,” Genes and Immunity, vol. 2, no. 8, pp. 461–463, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Wang, A. O. Y. Luk, R. C. W. Ma et al., “Independent predictive roles of eotaxin Ala23Thr, paraoxonase 2 Ser311Cys and β3-adrenergic receptor Trp64Arg polymorphisms on cardiac disease in type 2 diabetes—an 8-year prospective cohort analysis of 1297 patients,” Diabetic Medicine, vol. 27, no. 4, pp. 376–383, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. H. S. Chang, J. S. Kim, J. H. Lee et al., “A single nucleotide polymorphism on the promoter of eotaxin1 associates with its mRNA expression and asthma phenotypes,” The Journal of Immunology, vol. 174, no. 3, pp. 1525–1531, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Rigoli, L. Caminiti, C. Di Bella et al., “Investigation of the eotaxin gene −426C → T, −384A → G and 67G → A single-nucleotide polymorphisms and atopic dermatitis in Italian children using family-based association methods,” Clinical and Experimental Dermatology, vol. 33, no. 3, pp. 316–321, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. E. W. J. A. Albrecht, C. A. Stegeman, P. Heeringa, R. H. Henning, and H. van Goor, “Protective role of endothelial nitric oxide synthase,” The Journal of Pathology, vol. 199, no. 1, pp. 8–17, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. X. L. Wang, M. C. Mahaney, A. S. Sim et al., “Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 11, pp. 3147–3153, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Nakayama, H. Yasue, M. Yoshimura et al., “T−786 → C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm,” Circulation, vol. 99, no. 22, pp. 2864–2870, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Máchal, A. Vašků, V. Kincl et al., “Association between three single nucleotide polymorphisms in eotaxin (CCL 11) gene, hexanucleotide repetition upstream, severity and course of coronary atherosclerosis,” Journal of Applied Genetics, vol. 53, no. 3, pp. 271–278, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. V. Kincl, A. Vasků, J. Meluzín, R. Panovský, J. Seménka, and L. Groch, “Association of the eNOS 4a/b and -786T/C polymormphisms with coronary artery disease, obesity and diabetes mellitus,” Folia Biologica, vol. 55, pp. 187–191, 2009. View at Google Scholar
  32. T. R. Gaunt, S. Rodriguez, C. Zapata, and I. N. M. Day, “MIDAS: software for analysis and visualisation of interallelic disequilibrium between multiallelic markers,” BMC Bioinformatics, vol. 7, article 227, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Ardigo, T. L. Assimes, S. P. Fortmann et al., “Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease,” Physiological Genomics, vol. 31, no. 3, pp. 402–409, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. D. E. Mosedale, D. J. Smith, S. Aitken et al., “Circulating levels of MCP-1 and eotaxin are not associated with presence of atherosclerosis or previous myocardial infarction,” Atherosclerosis, vol. 183, no. 2, pp. 268–274, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Canouï-Poitrine, G. Luc, Z. Mallat et al., “Systemic chemokine levels, coronary heart disease, and ischemic stroke events: the PRIME study,” Neurology, vol. 77, no. 12, pp. 1165–1173, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. C. A. Wyss, M. Neidhart, L. Altwegg et al., “Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes,” European Heart Journal, vol. 31, no. 12, pp. 1457–1469, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. R. B. Kodali, W. J. H. Kim, I. I. Galaria et al., “CCL11 (Eotaxin) induces CCR3-dependent smooth muscle cell migration,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 7, pp. 1211–1216, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Hao, G. Gabbiani, and M.-L. Bochaton-Piallat, “Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 9, pp. 1510–1520, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. S. M. Schwartz, D. DeBlois, and E. R. M. O'Brien, “The intima: soil for atherosclerosis and restenosis,” Circulation Research, vol. 77, no. 3, pp. 445–465, 1995. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Nakamura, A. D. Luster, T. Nakamura et al., “Variant eotaxin: its effects on the asthma phenotype,” Journal of Allergy and Clinical Immunology, vol. 108, no. 6, pp. 946–953, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. T.-N. Wang, W. Chiang, H.-I. Tseng et al., “The polymorphisms of Eotaxin 1 and CCR3 genes influence on serum IgE, Eotaxin levels and mild asthmatic children in Taiwan,” Allergy, vol. 62, no. 10, pp. 1125–1130, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. B. V. Loughrey, A. McGinty, I. S. Young, D. R. McCance, and L. A. Powell, “Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low-dose atorvastatin treatment: evidence from a randomized controlled trial,” Clinical Endocrinology, vol. 79, no. 6, pp. 800–806, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. W. Wang, W. Le, R. Ahuja, D.-Y. Cho, P. H. Hwang, and D. Upadhyay, “Inhibition of inflammatory mediators: role of statins in airway inflammation,” Otolaryngology: Head and Neck Surgery, vol. 144, no. 6, pp. 982–987, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. A. A. Zeki, P. Thai, N. J. Kenyon, and R. Wu, “Differential effects of simvastatin on IL-13-induced cytokine gene expression in primary mouse tracheal epithelial cells,” Respiratory Research, vol. 13, article 38, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Sheikine, B. Olsen, B. Gharizadeh, K. Jatta, P. Tornvall, and M. Ghaderi, “Influence of eotaxin 67G>A polymorphism on plasma eotaxin concentrations in myocardial infarction survivors and healthy controls,” Atherosclerosis, vol. 189, no. 2, pp. 458–463, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Y. L. Zee, N. R. Cook, S. Cheng et al., “Threonine for alanine substitution in the eotaxin (CCL11) gene and the risk of incident myocardial infarction,” Atherosclerosis, vol. 175, no. 1, pp. 91–94, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. T. B. Opstad, H. Arnesen, A. Å. Pettersen, and I. Seljeflot, “The MMP-9 -1562 C/T polymorphism in the presence of metabolic syndrome increases the risk of clinical events in patients with coronary artery disease,” PLoS ONE, vol. 9, no. 9, Article ID e106816, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. T. B. Opstad, A. Å. Pettersen, H. Arnesen, and I. Seljeflot, “The co-existence of the IL-18+183 A/G and MMP-9 -1562 C/T polymorphisms is associated with clinical events in coronary artery disease patients,” PLoS ONE, vol. 8, no. 9, Article ID e74498, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Humphries, C. Bauters, A. Meirhaeghe, L. Luong, M. Bertrand, and P. Amouyel, “The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis,” European Heart Journal, vol. 23, no. 9, pp. 721–725, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Rai, F. Parveen, S. Kumar, A. Kapoor, and N. Sinha, “Association of endothelial nitric oxide synthase gene polymorphisms with coronary artery disease: an updated meta-analysis and systematic review,” PLoS ONE, vol. 9, no. 11, Article ID e113363, 2014. View at Publisher · View at Google Scholar · View at Scopus